Microbot Medical Inc reports results for the quarter ended June 30 - Earnings Summary
12/08/2025 22:55
Microbot Medical Inc MBOT.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -17 cents. The lone analyst forecast for the quarter was for a loss of 8 cents per share. Reported revenue was zero; analysts expected zero. Microbot Medical Inc's reported EPS for the quarter was a loss of 10 cents. Microbot Medical Inc shares had risen by 14.7% this quarter and gained 158.0% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 33.3% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Microbot Medical Inc is $9.00, about 65.3% above its last closing price of $3.12 This summary was machine generated from LSEG data August 12 at 09:55 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.08 | -0.10 | Missed |
| Mar. 31 2025 | -0.13 | -0.09 | Beat |
| Dec. 31 2024 | -0.18 | -0.20 | Missed |
| Sep. 30 2024 | -0.17 | -0.20 | Missed |
Recent news on Microbot Medical
See all newsBrief: Microbot Medical® Enters Into An Agreement To Expand Access For America’S Veteran And Military Patient Populations
Microbot Medical rises as U.S. federal supply deal expands reach of robotic surgical device
Brief: Microbot Medical Recorded Revenue During Its Quarter Ended March 31, Benefiting From Limited Market Release Of Liberty System
Brief: Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites
Brief: Microbot Medical Continues Its 2025 Momentum Announces Key 2026 Milestones